The influence of bisoprolol dose on ADP-induced platelet aggregability in patients on dual antiplatelet therapy

Coronary Artery Disease

Volumn 21, Issue 8, 2010, Pages 472-476

  Ignjatovic, Vladimir Slavisa ^a   Petrovic, Njegos ^a   Miloradovic, Vladimir ^a   Ignjatovic, Snezana ^b   Cokanovic, Vesna ^a   Grdinic, Aleksandra ^c   Simic, Ivan ^a   Petrovic, Ivica ^b   Nikolic, Sara ^b   Andjelkovic, Aleksandar ^b   Paramentic, Dusan ^b   Ignjatovic, Slavisa ^a  

^a CLINICAL CENTER KRAGUJEVAC   (Serbia)

^b Medical Faculty Kragujevac   (Serbia)

^c University Clinical Hospital Center Dr DragisaMisovic Dedinje   (Serbia)

Author keywords

ADP test; bisoprolol; clopidogrel; platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; AMIODARONE; ATORVASTATIN; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; DIGITALIS; DIURETIC AGENT; HEPARIN; METOPROLOL; NEBIVOLOL; NITRATE; OMEPRAZOLE; PANTOPRAZOLE; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANALYZER; ANTICOAGULATION; ARTICLE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; ANGIOPLASTY, BALLOON, CORONARY; BISOPROLOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SERBIA; STENTS;

EID: 78649513065     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32833fd25b     Document Type: Article

References (32)

1. CURE: Steering Committee. Effects of vlopidogrel in addition to aspirin in patients with acute coronary syndromes without ST elevation. N Engl J Med 2001; 345:494-502.
2. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A,Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. CREDO investigators. clopidogrel for the reduction of events during observation. JAMA 2002; 288:2411-2420.
3. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108:989-995.
4. Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehall H. Aspirin and clopidogrel resistance. Mayo Clin Proc 2006; 81:518-526.
5. Lee JM, Park S, Shin DJ, Choi D, Shim CY, Ko YG, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009; 104:46-51.
6. Wang T, Bhatt D, Topol E. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J 2006; 27:647-654.
7. Soffer D, Moussa I, Harjai K, Boura J, Dixon S, Grines C, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003; 59:21-25.
8. Sibbing D, Morath T, Stegher J, Braun S, Vogt W, Hadamitzky M, et al. Impact of proton pump inhibitors on the platelet effects of clopidogrel. Thromb Haemost 2009; 101:714-719.
9. Angiolillo D, Alfonso F. Clopidogrel-statin interaction. J Am Coll Cardiol 2007; 4:296-298.
10. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52:1557-1563.
11. Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg G, Montalescot G, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009; 120:2337-2344.
12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54:2430-2435.
13. Von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, et al. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry. Blood Coagul Fibrinolysis 2010; 21:46-52.
14. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: Executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27:1341.
15. Weksler BB, Gillick M, Pink J. Effect on propranolol on platelet function. Blood 1977; 49:185-196.
16. Petrikova M, Jancinova V, Nosal R, Majekova M, Fabryova V. Carvedilol-b blocker with considerable antiaggregatory effect on human blood platelets. Bratisl Lek Listy 2005; 106:20-25.
17. Falciani M, Rinaldi B, D'Agostino B, Mazzeo F, Rossi S, Nobili B, et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001; 38:922-929.
18. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high risk patients undergoing vascular surgery. N Engl J Med 1999; 341:1789-1794.
19. Sayer JW, Gutteridge C, Syndercombe-Court D, Wilkinson P, Timmis AD. Circadian activity of fibrinolytic system in stable coronary artery disease: Effects of beta adrenoceptorblocker and angiotensin converting enzyme inhibitors. J Am Coll Cardiol 1998; 32:1962-1968.
20. Schwartz C, Neville A. Catecholamines and platelet aggregation. Circ Res 1967; 21 (Suppl III):187-202.
21. Mills B, Roberts K. Effects of adrenaline on human blood platelets. J Psysiol 1967; 193:443-453.
22. Sorkin RP, Tokarsky JM, Huber-Smith MJ, Steiger JF, McCann DS. In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction. Am Heart J 1982; 104:1255-1261.
23. Andrews NP, Gralnick HR, Merryman P, Vail M, Quyyumi AA. Mechanisms underlying the morning increase in platelet aggregation: A flow cytometry study. J Am Coll Cardiol 1996; 28:1789-1795.
24. Levites R, Haft JI. Effects of exercise-induced stress on platelet aggregation. Cardiology 1975; 60:304-314.
25. Wallén NH, Held C, Rehnqvist N, Hjemdahl P. Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls. Eur Heart J 1997; 18:807-815.
26. Pietraszek MH, Takada Y, Takada A. Effect of mental stress on platelet aggregation: Possible link to catecholamine levels. Haemostasis 1991; 21:346-352.
27. Wang J-S, Li Y-S, Chen J-C, Chen Y-W. Effects of exercise training and deconditioning on platelet aggregation induced by alternating shear stress in men. Arterioscler Thromb Vasc Biol 2005; 25:454-460.
28. Petidis K, Douma S, Doumas M, Basagiannis I, Vogiatzis K, Zamboulis C. The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. BMC Cardiovasc Disord 2008; 8:11. doi: 10.1186/1471-2261-8-11. (Pubitemid 351891417)
29. Venkataraman BV, Rani N. Platelets and antiplatelet drugs. Indian J Pharmacol 1992; 24:188-193.
30. Campbell WB, Callahan KS, Johnson AR, Graham RM. Antiplatelet activity of beta-adrenergic antagonist: Inhibition of tromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. Lancet 1981; 318:1382-1384.
31. Nayle WG. The effect of pronethalol and propranolol on lipid facilitated transport of Calcium ions. J Pharmacol Exp Ther 1966; 153:479-484.
32. Vilén L, Kutti J, Swedberg K, Vedin A. ADP-induced platelet aggregation and metoprolol treatment of myocardial infarction patients: A controlled study. Acta Med Scan 1985; 217:15-20.